Table 2.

Unadjusted associations of recent medication use with time to oral HPV clearance among 594 participants with 1,358 oral HPV infections

Medication type used since last visita	No. of cleared infections	Person-months of observation	HR (95% CI)
Antipsychoticsb
HIV-uninfected (n=299)
No	122	3,968	Ref
Yes	13	273	1.38 (0.88–2.17)
HIV-infected (n=1,059)
No	466	14,998	Ref
Yes	46	2,298	0.67 (0.49–0.91)
Anxiolytics/sedatives
No	512	16,123	Ref
Yes	135	5,415	0.78 (0.63–0.96)
Antidepressants
No	466	14,415	Ref
Yes	181	7,123	0.82 (0.67–0.99)
Asthma (steroidal) medications
No	572	19,288	Ref
Yes	75	2,250	1.20 (0.89–1.63)
Asthma (non-steroidal) medications
No	489	16,349	Ref
Yes	158	5,189	1.06 (0.87–1.28)
Cholesterol-lowering medications
No	469	15,742	Ref
Yes	178	5,796	1.03 (0.86–1.25)
Diabetes medications
No	567	19,231	Ref
Yes	80	2,307	1.19 (0.92–1.53)
Hormones
No	618	20,665	Ref
Yes	29	872	1.10 (0.72–1.69)
Hypertension medications
No	397	13,246	Ref
Yes	250	8,292	1.02 (0.86–1.22)
NSAIDs
No	419	11,760	Ref
Yes	203	6,673	0.90 (0.76–1.07)
Erectile dysfunction medications (men only)
No	296	9,952	Ref
Yes	56	2,419	0.77 (0.58–1.01)

^aAll medication use variables were time-updated (i.e. medication use reported at each visit was applied to the WLW model, and was allowed to change if the participant started/stopped medication use). If a participant missed a visit, the last reported medication use status was used in the analysis.

Statistically significant values are listed in bold. Statistical significance was defined as two-sided p-value <0.05.

^bAntipsychotic medication use was associated with reduced clearance in HIV-infected participants only (p-interaction=0.009)